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Jayer Chung, MD, David A. Timaran, MD, J. Gregory Modrall, MD, Chul Ahn, PhD,
Carlos H. Timaran, MD, Melissa L. Kirkwood, MD, Mirza S. Baig, MD, and R. James Valentine, MD,
Dallas, Tex
Objective: Determine the proportion of patients with chronic critical limb ischemia (CLI) who failed to adhere to Trans-
Atlantic Inter-Society Consensus II guidelines of medical therapy and to quantify the effect of baseline suboptimal
medical management on amputation-free survival (AFS).
Methods: The patients were identiﬁed from a prospectively maintained database of consecutive patients presenting with
CLI to the Vascular Surgery service at a single hospital. The primary outcome variable was AFS. The effects of baseline
demographics, comorbid medical conditions, ambulatory status, optimal medical management, and Rutherford classiﬁ-
cation were assessed. Signiﬁcant univariate predictors (P < .10) of AFS were entered into a multivariate Cox proportional
hazards model.
Results: From August 1, 2010 through January 1, 2012, 98 patients (median age, 59.0; interquartile range, 53, 64 years;
58 men) were evaluated with rest pain (n[ 40) or tissue loss (n[ 58). Optimal medical management was identiﬁed in 31
(32%) patients at initial presentation. Compliance rates for the entire cohort were 61% for statin use, 69% for antiplatelet
therapy, 56% for angiotensin-converting enzyme inhibitor use, and 53% for beta-blocker use. Signiﬁcant univariate
predictors of major amputation or death included: Rutherford classiﬁcation (hazard ratio [HR], 1.56; 95% conﬁdence
interval [CI], 1.01-2.41; P [ .04); nonambulatory status (HR, 2.17; 95% CI, 1.68-2.81; P < .01); unrevascularized
patients (HR, 2.77; 95% CI, 1.32-5.85; P < .01); a history of tobacco abuse (HR, 1.49; 95% CI, 0.57-3.86; P [ .09);
a history of end-stage-renal disease (HR, 7.97; 95% CI, 3.10-20.52; P < .01); suboptimal medical management (HR,
4.25; 95% CI, 1.28-14.07; P [ .02); and an absence of antiplatelet agents (HR, 1.94; 95% CI, 0.92-4.11; P [ .08).
Independent predictors of major amputation or death included: initial nonambulatory status (HR, 2.43; 95% CI, 1.03-
2.05; P < .01); unrevascularized status (HR, 2.43; 95% CI, 1.76-3.34; P[ .01); and suboptimal medical management at
presentation (HR, 8.54; 95% CI, 2.05-35.65; P < .01).
Conclusions: Despite guidelines advocating the optimization of atherosclerotic risk factors, less than one-third of patients
with CLI present with their risk factors optimally managed. Patients who are medically undertreated have an eight-fold
risk of major amputation and/or death. The magnitude of the effect suggests that future trials and quality assessments
should stratify outcomes by the quality of baseline medical management. Of the risk factors affecting AFS medical
therapy optimization is the variable that can be most signiﬁcantly improved by vascular surgeons and the medical
community. (J Vasc Surg 2013;58:972-80.)Chronic critical limb ischemia (CLI) is an increasingly
prevalent public health problem, with an estimated annual
incidence of 500 to 1000 cases/million in a Western pop-
ulation.1 In the United States, the proportion of older
adults at risk of developing CLI is increasing, with approx-
imately 20% of the population expected to be aged $65
years by the year 2030.2 The risk of CLI is ampliﬁed by
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amputations at 1 year, either an above-the-knee amputa-
tion (AKA) or below-the-knee amputation (BKA) occur
in approximately 20% to 40% of untreated CLI patients,4,5
and in approximately 12% of patients after open revascular-
ization.6 At 5 years, patients with symptomatic peripheral
arterial disease (PAD) have a 20% to 30% risk of a nonfatal
myocardial infarction or stroke.7
Accumulating evidence suggests that improving medical
management of patients with PAD will improve graft and/
or stent patency, and overall mortality, particularly antiplate-
let agents,8,9 statins,10,11 and beta-blockers.12,13 This has
resulted in the publication of guidelines from several socie-
ties1,14 to increase awareness and effect population-level
interventions to optimize medical therapy for PAD. Unfor-
tunately, multiple authors document a persistent, signiﬁcant
deﬁcit in the adherence to published guidelines for athero-
sclerosis risk-factor management.15-17 This deﬁcit should
be most pronounced for the CLI population, which repre-
sents the most severe manifestation of PAD.18
The signiﬁcance of undertreatment, while studied in the
overall PAD population, has not been well characterized
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in CLI limited their cohort to patients undergoing revascu-
larization,16,17 which has two problems: (1) confounding by
indication,19 which renders estimates of the effect of medical
undertreatment upon the entire CLI population inaccu-
rate, precluding policy-makers’ ability to accurately assess
population-level interventions to improve outcomes in
CLI. This occurs because the severity of medical undertreat-
ment is less, due to surgeon selection; and (2) limiting study
to those that are revascularized prevents one from evaluating
the relative importance of revascularization vs optimization
of medical therapy, for instance. The relative importance
of speciﬁc risk factors is key when determining which policy
interventions to undertake.
We therefore sought to quantify the risk-adjusted effect
of suboptimal medical therapy upon amputation-free
survival (AFS) in a cohort of CLI-only patients. We tested
the hypothesis that optimally medically managed CLI
patients, as deﬁned by adherence to TransAtlantic Inter-
Society Consensus (TASC) II guidelines, would have an
improved AFS relative to suboptimally managed CLI
patients. Secondarily, we aimed to describe the extent to
which atherosclerotic risk factors were managed within
our cohort of CLI patients.
METHODS
All consecutive patients presenting with CLI to the
Vascular Surgery Service at Parkland Memorial Hospital in
Dallas, Texas, between August 1, 2010 and January 1,
2012were prospectively entered into an outcomes database.
All CLI patients, regardless of whether they underwent an
operation, were included in the cohort. Institutional Review
Board approval (# 092011-043) was obtained prior to any
data collection or analysis. Each patient’s data were con-
ﬁrmed by review of the electronic medical record, with vital
status conﬁrmed by query of the Social Security Death
Index (http://ssdi.roots.web). One trained data abstractor
(D.T.) abstracted all of the data, which was then veriﬁed for
accuracy by a single vascular surgeon (J.C.).
Patients and demographics. The diagnosis of CLI
was made if patients presented with$2 weeks of symptoms
of ischemic rest pain, ulcerations, or gangrene in the pres-
ence of empiric evidence of hemodynamic insufﬁciency,
as deﬁned previously.1,5 Patients with nonatherosclerotic
disease, intermittent claudication only, antecedent acute
limb ischemia, or patients with prior major amputation to
the index limb were excluded.
Demographic data included baseline age, gender,
and medical comorbidities including chronic obstructive
pulmonary disease, coronary artery disease, congestive
heart failure, hypertension, hypercholesterolemia, diabetes
mellitus, and dialysis-dependent end-stage renal disease
(ESRD). Also recorded was a history of tobacco abuse, prior
myocardial infarction, arrhythmia, coronary artery bypass
grafting, percutaneous coronary intervention, prior lower
extremity revascularizations, prior stroke, and hypercoagu-
lable states. The severity of ischemia was described by
the Rutherford classiﬁcation.18 Baseline laboratory dataincluded white blood cell count (103 cells/mL), hemo-
globin (g/dL), platelet count (103 cells/mL), serum creat-
inine (mg/dL), and glomerular ﬁltration rate (mL/min/
1.73 m2). Hemoglobin A1C (HbA1C; %), low-density lipo-
protein (mg/dL), high-density lipoprotein (mg/dL), total
serum cholesterol (mg/dL), and serum triglyceride level
(mg/dL) were also abstracted using data within 6 months
of presentation. The baseline use of 3-HMG co-A reductase
inhibitors (statins), angiotensin-converting enzyme inhibi-
tors (ACE-Is), beta-blockers, anticoagulants (warfarin or
enoxaparin), or antiplatelet agents (aspirin or clopidogrel)
was documented. Baseline ambulatory status (indepen-
dent, with an assist device, nonambulatory), initial living
status (independent, community assisted/nursing home),
ethnicity (Caucasian, African-American, Hispanic, and
other), primary language (English, Spanish, or other), and
insurance status (Medicare or none) were also recorded.
All endovascular, open, and hybrid procedures were
deﬁned as revascularizations. These procedures were
further stratiﬁed into endovascular (balloon angioplasty,
atherectomy, and/or stenting), open (bypass or endarterec-
tomy), or hybrid (combination of open and endovascular)
revascularizations.
Deﬁnition of optimal medical management, AFS,
and limb-salvage. Patients were dichotomized and
deﬁned as optimally medically managed if the patient
showed evidence of adherence to all TASC II guidelines of
medical therapy at baseline (Table I).1 If one risk factor
was not optimally managed, the patient was deﬁned
as undertreated. Hypertensive patients were deemed
suboptimally managed if there were: (1) more than three
episodes of blood pressure measurements $140/90 mm
Hg during the index admission; or (2) more than three
episodes of blood pressure measurements $140/90 mm
Hg within the 6 months prior to the ﬁrst clinic visit.
For patients with concurrent diabetes or chronic renal
insufﬁciency, a cutoff value of 130/80 mm Hg was
used instead. Hypertensive patients were deﬁned as
undertreated if they were not on an ACE-I or thiazide
diuretic without a documented contraindication. Beta-
blockers and other antihypertensives were not included
in the deﬁnition of optimal therapy. While they are
acceptable alternatives to attain blood pressure control,
they do not represent best therapy of hypertension
as deﬁned by TASC II. Hypercholesterolemic patients
were deﬁned as undertreated if the serum low-density
lipoprotein within the 6 months prior to presentation
measured greater than 70 mg/dL if there was evidence
of atherosclerosis in multiple vascular beds. Otherwise,
a cutoff value of 100 mg/dL was utilized. For
hypercholesterolemics, an absence of statin therapy was
included in the deﬁnition of suboptimal management. All
current smokers were considered undertreated, regardless
of whether other risk factors were optimally managed. An
HbA1c value #7.0% distinguished between optimally
managed and undertreated diabetics. The frequency of
antiplatelet agents was also documented. To be optimally
managed, subjects needed to be taking either aspirin or
Table I. TransAtlantic Inter-Society Consensus (TASC) II guidelines utilized to determine optimal medical therapy at
baseline presentation
Atherosclerotic risk
factor TASC II recommendation
Deﬁnition of optimal medical
therapy in CLI
Tobacco abuse 1. All patients who smoke should be strongly and
repeatedly advised to stop smoking
2. All patients who smoke should receive a
program of physician advice, group counseling
sessions, and nicotine replacement
3. Cessation rates can be enhanced by the
addition of antidepressant drug therapy and
nicotine replacement
No smoking
Hyperlipidemia 1. All symptomatic and asymptomatic
PAD patients should have their LDL
cholesterol lowered to <100 mg/dL (<70
mg/dL if a history of vascular disease in
other beds)
2. In symptomatic PAD patients, statins
should be the primary agents to lower LDL
cholesterol levels to reduce the risk of
cardiovascular events
1. LDL cholesterol <100 mg/dL (<70 mg/dL if
a history of vascular disease in other beds)
2. On statin therapy unless contraindicated
Hypertension 1. All hypertensive patients should have
blood pressure controlled to <140/90 mmHg
(<130/80 mm Hg if concurrent diabetes or
renal insufﬁciency)
2. Thiazides and ACE inhibitors should
be considered as initial blood-pressure
lower drugs in PAD to reduce the risk of
cardiovascular events
1. Blood pressure <140/90 mm Hg
(<130/80 mm Hg if concurrent diabetes
or renal insufﬁciency)
2. On an ACE inhibitor or thiazide diuretic
unless contraindicated
Diabetes mellitus 1. Patients with diabetes and PAD should
have aggressive control of blood glucose levels
with an HbA1c goal of <7.0% or as close to
6.0% as possible
HbA1c of <7.0%.
Antiplatelet therapy 1. All symptomatic patients with or
without a history of other cardiovascular
disease should be prescribed an antiplatelet
drug long term
2. Clopidogrel is effective in reducing
cardiovascular events in a subgroup of patients
with symptomatic PAD
On aspirin and/or clopidogrel unless
contra-indicated
ACE, Angiotensin-converting enzyme; CLI, chronic critical limb ischemia; HbA1c, hemoglobin A1c; LDL, low-density lipoprotein; PAD, peripheral arterial
disease.
Patients were deﬁned as optimally medically managed if they adhered to all of the TASC II guidelines as summarized above.
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Patients with the diagnosis of either hyperlipidemia or
diabetes with missing lipid panels or HbA1c data were
assumed to be undertreated. Exploratory analyses were
performed where the number of optimally managed
factors was an ordinal variable, to capture whether the
severity of undertreatment was associated with AFS.
For revascularized subjects, the duration of AFS (days)
was deﬁned as the time from the operation, to the time of
death, AKA, or BKA. For unrevascularized subjects, AFS
was deﬁned as the time between the initial vascular surgery
consultation to the time of death, AKA, or BKA. Limb
salvage was deﬁned as the time from the ﬁrst operativeattempt to the time of either an AKA or BKA (days). For
subjects who were not revascularized, limb salvage was
deﬁned as the time between the initial vascular surgery
consultation to either the time of AKA or BKA. Overall
survival was deﬁned as the time from the initial vascular
surgical consultation to either the date of death, or date of
last known follow-up (days).
Procedural details. The decision to perform and
the speciﬁcs of a revascularization or primary major ampu-
tation was made at the discretion of the attending physician
(JC, JGM, RJV), and entailed an assessment of the clinical
and anatomic features and functional status of the patient
in conjunction with detailed patient counseling. An
JOURNAL OF VASCULAR SURGERY
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subjects. All revascularizations were performed within the
hybrid operating room if ﬂuoroscopy was required. Medical
management of the individual patients after presentation
was instituted at the discretion of the attending physician.
End points and statistical analysis plan. The primary
end point was AFS at last known follow-up. Secondarily,
the limb-salvage and survival rates were also compared to
clarify the main determinant of the combined end point.
Causes of death were deﬁned as: (1) cardiac (myocardial
infarction, arrhythmia, congestive heart failure); (2) stroke;
(3) pulmonary (pneumonia, acute respiratory distress
syndrome, chronic obstructive pulmonary disease exacer-
bation); (4) renal failure; (5) malignancy; and (6) other. The
effect of medical comorbidities, baseline laboratory values,
medication use, baseline functional status, baseline ischemic
severity, and the duration of ischemia upon actuarial
estimated AFS was evaluated among the entire population.
Descriptive statistics are presented as a median and
interquartile range (IQR) for continuous data and frequen-
cies and percentages for categorical data. AFS, limb salvage,
and overall survival was evaluated using survival analysis
and Cox proportional hazards regression or Kaplan-Meier
analysis where appropriate. Hazard ratios (HRs) are pre-
sented with 95% conﬁdence intervals (CIs). All variables
were entered into a univariate Cox regression model;
candidate covariates for multivariate modeling were
selected based on P < .10 and statistical signiﬁcance was
assessed at a ¼ .05. Subsequent Kaplan-Meier analyses
were performed to evaluate the effect of optimal medical
therapy upon limb salvage and survival individually. Actu-
arial survival estimates are presented as a mean 6 standard
error (SE). Data were analyzed with SAS 9.3 (SAS Institute
Inc, Cary, NC).
RESULTS
Demographics and optimal medical therapy.
Ninety-eight patients (58 men) with a median age of 59.0
years (IQR, 53-64 years) presented with CLI during the
study period. Forty patients (40%) presented with rest
pain (Rutherford class 4), while 27 patients (28%) pre-
sented with minor tissue loss (Rutherford class 5). Thirty-
one patients (32%) presented with extensive tissue loss
(Rutherford class 6). At baseline, 32% of patients (n ¼ 31)
presented with optimal medical management. Most sub-
jects had a history of hypertension, diabetes mellitus,
hypercholesterolemia, and tobacco abuse. Of the 67 sub-
optimally managed patients, three (3%) had three risk fac-
tors that were undertreated, whereas 31 (32%) subjects had
two risk factors undertreated. The remaining 33 patients
(65%) had one known risk factor inappropriately managed.
Guideline compliance for medication use was best for
antiplatelet therapy and statin use; however, ACE-inhibitor
use and beta-blocker administration was slightly greater
than 50% (Table II).
Major amputation and death. Following evaluation
by a vascular surgeon, 12 patients underwent primary
amputation for nonambulatory status at presentation(n ¼ 5), disease that was deemed unreconstructable by the
attending physician (n ¼ 4), or extensive sepsis (n ¼ 3).
Sixty-eight subjects (69%) underwent revascularization (22
open, 33 endovascular, and 13 hybrid). Eighteen (18%)
patients did not have any surgery, most frequently due to
patient refusal (n ¼ 13), followed by medical comorbidities
precluding timely surgery with eventual loss to follow-up
(n ¼ 5). After a median follow-up of 302.0 days (IQR,
207-482 days), 31 patients met the primary end point.
Including subjects who underwent a primary amputation,
22 patients ultimately had a major amputation (17 AKAs,
and 5 BKAs). Eleven subjects ultimately died, one after
a major amputation. Causes of death at last follow-up were
unknown in ﬁve subjects, cardiac in three subjects,
pulmonary in two subjects, and due to renal failure in one
subject.
For the entire cohort, Kaplan-Meier 1-year estimated
AFS, limb-salvage rate, and overall survival was 68.9 6
5.1%, 78.3 6 5.0%, and 88.2 6 3.6%, respectively. Patients
who were revascularized experienced better outcomes rela-
tive to those not revascularized, with Kaplan-Meier esti-
mated 1-year AFS, limb salvage, and overall survival as
follows: 74.8 6 5.7% vs 52.5 6 10.0% (log rank, P ¼
.005); 77.8 6 6.2% vs 68.5 6 11.9% (log-rank, P ¼
.24); 93.6 6 3.6 vs 74.1 6 8.4% (log rank, P ¼ .002),
with the main determinant of the composite end point
being the improved overall survival in the revascularized
patients. No statistically signiﬁcant differences were
observed for AFS, limb-salvage rate, and overall survival
between patients revascularized with either an open revas-
cularization, endovascular revascularization, or a hybrid
revascularization (log-rank, P ¼ .92). Further subgroup
analysis was performed to examine the optimally medically
managed patients only, which revealed that subjects who
were optimally treated had a 1-year limb-salvage rate
of 97.1% compared with 83.4% in the unrevascularized
(log-rank, P < .01).
Effect of optimal medical management. When
comparing decedents and/or amputees vs survivors
with limb salvage, a higher proportion of subjects had
ESRD, diabetes mellitus, presented with tissue loss, were
non-ambulatory, and were suboptimally medically
managed (Table II). Cox regression failed to reveal a statis-
tically signiﬁcant association between the number of risk
factors that were undertreated and AFS (c2, P ¼ .68).
Diabetes management was most frequently inadequate,
with 16 of 62 diabetics (40% of diabetics) presenting with
an HbA1c #7.0%. Tobacco abuse was the next most
frequent mismanaged risk factor, with 51 patients (52%)
currently smoking. A higher proportion of survivors with
limb salvage had optimal control of their blood pressure,
and were on an antiplatelet agent when compared with
decedents with/without major amputation. A higher
proportion of current smokers survived without a major
amputation. Hyperlipidemia management was similar
among the two groups (Fig 1). No patient had a docu-
mented contraindication to aspirin, clopidogrel, statins, or
ACE-Is.
Table II. Patient baseline demographics
Variable
Status at follow-up
P
Alive, no major
amputation (n ¼ 67; 68.4%)
Deceased and/or
major amputation (n ¼ 31; 31.6%)
Median age, years (IQR) 59.0 (53-63) 61.0 (53-64) .39
Male 41 (61.2) 16 (51.6) .52
Medical comorbidities
Coronary artery disease 23 (34.3) 9 (29.0) .75
History of myocardial infarction 13 (19.4) 6 (19.4) .80
History of coronary bypass 10 (14.9) 2 (6.5) .28
History of percutaneous coronary
intervention
9 (13.4) 3 (9.7) .67
History of cardiac arrhythmia 3 (4.5) 3 (9.7) .28
History of prior stroke 8 (11.9) 2 (6.5) .58
Dialysis-dependent renal failure 0 (0) 6 (19.4) <.01
Hypertension 52 (77.6) 26 (83.9) .16
Diabetes mellitus 40 (59.7) 22 (70.9) .13
Hyperlipidemia 48 (71.6) 23 (74.1) .21
Chronic obstructive pulmonary disease 9 (13.4) 3 (9.7) .76
History of smoking 53 (79.1) 19 (61.3) .26
Current smokers 37 (55.2) 14 (45.1) .25
Medical managementa
Suboptimal medical management 42 (62.7) 25 (80.6) <.01
1 risk factor undertreated 19 (28.4) 14 (45.2) .13
2 risk factors undertreated 21 (31.3) 10 (32.2) .56
3 risk factors undertreated 2 (3.0) 1 (3.2) .96
Use of antiplatelet medication 51 (76.1) 17 (54.8) .08
Statin 41 (61.1) 19 (61.3) .69
ACE inhibitors 39 (58.2) 16 (51.6) .78
Beta-blockers 35 (52.2) 17 (54.8) .42
Vascular history
Prior revascularization to ipsilateral limb 25 (37.3) 12 (38.7) .46
Rutherford classiﬁcation 4 (rest pain) 31 (46.2) 9 (29.0) .34
Rutherford classiﬁcation 5 (minor tissue
loss)
16 (23.9) 11 (35.5) .25
Rutherford classiﬁcation 6 (major tissue
loss)
20 (29.9) 11 (35.5) .48
Independently ambulatory 49 (73.1) 6 (19.3) <.01
ACE, Angiotensin-converting enzyme; IQR, interquartile range; TASC, TransAtlantic Inter-Society Consensus.
Data are presented as number (%) unless otherwise indicated.
aCriteria of suboptimal medical therapy are deﬁned as adherence to TASC II guidelines as deﬁned in Table I.
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AFS. One-year KaplanMeier AFS was 88.36 6.4% for opti-
mally managed patients vs 60.4 6 6.4% for undertreated
patients (log-rank, P ¼ .009; Fig 2). Overall survival was
not statistically superior among patients who presented
with optimal medical therapy at baseline (log-rank, P ¼
.94). However, limb salvage was statistically signiﬁcantly
superior among patients presenting with optimal medical
therapy, with 1-year Kaplan-Meier estimated limb-salvage
rates of 95.8 6 4.1% vs 70.2 6 6.6% (log-rank, P ¼ .008).
Univariate and multivariate analysis. Variables that
were associated with an increased risk of major amputation
or death by univariate analysis (P < .10) included: a history
of tobacco abuse (HR, 1.49; 95% CI, 0.57-3.86; P > .09);
unrevascularized status (HR, 2.77; 95% CI, 1.32-5.85; P <
.01); baseline nonambulatory status (HR, 2.17; 95% CI,
1.68-2.81; P < .01); ESRD requiring dialysis (HR, 7.97;
95% CI, 3.10-20.52; P < .01); suboptimal medicalmanagement (HR, 4.25; 95% CI, 1.28-14.07; P ¼ .02); an
absence of antiplatelet agents (HR, 2.77; 95% CI, 0.92-
4.11; P ¼ .08); and the Rutherford class (HR, 1.56; 95%
CI, 1.01-2.41; P ¼ .04). No other variables were entered
into the multivariate model, which revealed that the
following factors independently predicted major amputa-
tion and/or death: initial nonambulatory status (HR, 2.43;
95% CI, 1.03-2.05; P < .01); unrevascularized patients
(HR, 2.71; 95% CI, 1.22-5.99; P ¼ .01); and suboptimal
medical management (HR, 8.54; 95% CI, 2.05-35.65; P <
.01; Table III).DISCUSSION
Baseline suboptimal medical therapy increases the risk of
major amputation and/or death by a factor of eight. Despite
guidelines advocating for improved medical management of
atherosclerosis, greater than two-thirds of CLI patients
Fig 1. Distribution of optimal management of atherosclerotic risk factors as deﬁned by the TransAtlantic Inter-Society
Consensus (TASC) II guidelines between survivors with limb salvage and decedents with/without major amputation.
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the primary end point suggests that suboptimal medical
therapy increases a patient’s risk of major amputation rather
than survival. The risk factors most undertreated among
decedents and/or major amputees were diabetes mellitus,
hypertension, and antiplatelet therapy.
Our data conﬁrms and quantiﬁes the persistent deﬁcit
in the quality of medical care in CLI and has two profound
implications. First, population-based interventions that
improve medical therapy for CLI may have a large impact
upon AFS, and may exceed the impact of revascularization
upon AFS. This effect is intuitive, and conﬁrmed by large
registry studies in PAD that show suboptimal medical
management can increase the risk of cardiovascular
death/nonfatal stroke/nonfatal myocardial infarction by
up to seven-fold at 3 years.21,22 Since the effect of medical
undertreatment can overwhelm that of revascularization,
population-based efforts to improve the quality of medical
therapy may improve outcomes in CLI more than revascu-
larization. Prior studies showing a gap between the quality
of medical therapy among coronary artery disease cohortsvs PAD cohorts22 prove that population-level improve-
ments are possible within current health delivery models.
The mechanism of observed deﬁcits in the PAD population
may include inadequate physician awareness15 and lack of
patient awareness of PAD.23
Secondly, assessment of outcomes in CLI may beneﬁt
from stratiﬁcation by the quality of baseline medical therapy.
Current performance guidelines do not include the effect of
medical therapy upon outcomes in CLI,24 which makes
comparisons between trials difﬁcult, as the large effect could
confound the outcomes. Moreover, failure to stratify by the
quality of baseline medical therapy also confounds compari-
sons between individual providers and institutions, which is
particularly germane in light of the recent passage of the
Affordable Care Act in 2010,25 and the pending creation
of Accountable Care Organizations.26 The inability to adjust
for the effect of medical undertreatment precludes providers
and institutions from accurately determining the quality of
the vascular care delivered. Given the large effect observed
in our data, we advocate that future studies and quality
assessments include medical management data points to
Fig 2. Amputation-free survival (AFS) among 98 chronic critical limb ischemia (CLI) patients stratiﬁed by optimal
medical therapy at presentation. SE, Standard error.
Table III. Univariate and multivariate Cox regression analyses for AFS and last known follow-up
Variable Unadjusted HR (95% CI) P Adjusted HR (95% CI) P
Tobacco abuse 1.49 (0.57-3.86) .09
Unrevascularized 2.77 (1.32-5.85) <.01 2.71 (1.22-5.99) .01
Initial nonambulatory status 2.17 (1.68-2.81) <.01 2.43 (1.03-2.05) <.01
ESRD 7.97 (3.10-20.52) <.01
Suboptimal medical management 4.25 (1.28-14.07) .02 8.54 (2.05-35.65) <.01
Absence of antiplatelet agents 1.94 (0.92-4.11) .08
Rutherford classiﬁcation 1.56 (1.01-2.41) .04
AFS, Amputation-free survival; CI, conﬁdence interval; ESRD, end-stage renal disease; HR, hazard ratio.
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hospitals, and help to enable equitable compensation in
Accountable Care Organizations.
Inclusion of the nonambulatory and unrevascularized
patients provided for the most accurate quantiﬁcation of
the effect of medical undertreatment upon AFS by elimi-
nating the bias of surgeons to operate upon the most ﬁt,
and hence, most optimally medically managed patients.
Unrevascularized patients were almost three times as likely
to have a major amputation or die in our patient cohort,
with $50% of unrevascularized subjects experiencing
a major amputation or death at 1 year. Prior trials
describing the natural history of CLI patients that did
not undergo revascularization did not contain a control
arm with revascularization.4,5,27 Nonetheless, the rates of
major amputation or death in our trial are similar to prior
reports.4,5,24 In our cohort, the beneﬁts of revasculariza-
tion appear limited to the subgroup that was optimallymedically managed, though further prospective analyses
are required to conﬁrm this ﬁnding.
Patients’ baseline nonambulatory status also predicts
major amputation and/or death, which validates 20-year-
old data describing outcomes after infrainguinal
bypass.28,29 The failure of tobacco abuse, Rutherford clas-
siﬁcation, and antiplatelet use to independently predict AFS
is a function of collinearity, as these risk factors are compo-
nents of the optimal medical therapy variable that ulti-
mately independently predicted AFS. Dialysis dependence
failed to independently predict AFS, as there were too
few subjects within the cohort with ESRD to affect the
model as a whole. While many diabetics were undertreated,
diabetes failed to reach statistical signiﬁcance on univariate
analysis. This further validates our hypothesis that it is the
conﬂuence of mismanaged atherosclerotic risk factors that
predicts major amputation and/or death, and not any
single risk factor alone.
JOURNAL OF VASCULAR SURGERY
Volume 58, Number 4 Chung et al 979Although our study has demonstrated a clear association
between suboptimal medical management and AFS,
a number of limitations exist. The results are dependent
on the status of medical therapy at the time of presentation.
Also, there were somemissing data, particularly with regards
to laboratory data, and to whether the patients were not
taking medications due to a known contraindication to
that therapy. This likely resulted in an inaccurate number
of undertreated factors. This problem was mitigated by
dichotomizing the predictor variable. While the data were
collected prospectively, the data abstraction depended
upon the judgment of the clinicians caring for the patient
prior to presentation and the patients’ self-reported history.
Thus, we could not conﬁrm all of the risk factors to which
each patient was exposed, nor the duration of exposure.
Our group does not have a regimented application of
optimal medical therapy after vascular surgical consultation,
so the effect of improving medical therapy cannot be ascer-
tained in our study.
Secondly, our study size is relatively limited. Hence, our
study failed to identify an association between the number
of undertreated risk factors, and poorer outcomes, as found
by other investigators in PAD.30 This also limited our ability
to perform a propensity score analysis, which would have
mitigated the selection bias that confounds the true effect
of revascularization on AFS in our cohort. We also could
not adjust for the severity of undertreated risk factors. For
example, we could not discern the difference between an
HbA1c of 7.5 and an HbA1c of 14. In addition, our dataset
is drawn from the inner city of Dallas, without insurance
and poor access to care prior to initial presentation, which
is distinct from other CLI populations. However, the
magnitude of the effect of suboptimal medical therapy
may render differences between different CLI populations
moot. Large prospective, multi-institutional studies will be
required to surmount these issues and determine the gener-
alizability of our results.
CONCLUSIONS
Optimization of medical therapy in the CLI population
can potentially improve AFS, as suboptimal medical therapy
increases the risk of major amputation and/or death by
eight-fold. Diabetes mellitus, hypertension, and application
of antiplatelet therapy were frequently undertreated and
represent excellent initial targets for population-based inter-
ventions to improve guideline adherence, and perhaps AFS.
Future trials and quality control efforts may beneﬁt from the
inclusion of baseline medical therapy data points for appro-
priate risk adjustment of outcomes.AUTHOR CONTRIBUTIONS
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